Cartalax
also known as cartilage bioregulator
Short-chain peptide bioregulator from the Khavinson school, derived from cartilaginous tissue extracts. Investigated for chondrogenic differentiation of mesenchymal stem cells and osteoprotective effects in ovariectomised rat models. Russian-tradition research with limited Western indexing; mechanistic data on cartilage matrix proteins (COL2, SOX9, ACAN) and bone mineral density preservation.
At a glance
SQ · Protocol Unspecified
Primary target — Mesenchymal stem cells (MSCs) undergoing chondrogenic differentiation [linkova-2023].
Pathway — Modulation of WNT, ERK-p38, and Smad 1/5/8 signaling pathways [linkova-2023].
Downstream effect — Upregulation of chondrogenic genes (COL2, SOX9, ACAN); increased bone mineral density; osteoprotective effects in ovariectomy-induced osteoporosis [linkova-2023][povorozniuk-2007].
Origin — Derived from cartilaginous tissue extracts (Khavinson bioregulator methodology) [povorozniuk-2007].
| Parameter | Value |
|---|---|
| Animal model dose | Unspecified (cartilaginous tissue extract protocol)Rat study; extract preparation details not indexed in available abstracts. |
| Human dosing | Not established in PubMed-indexed literatureRussian-tradition protocols exist but lack peer-reviewed Western validation. |
| Evidence basis | Animal mechanistic studies only |
Reconstitution
A pure mass-to-volume utility. Enter what you have in the vial; the atlas computes the volume per dose. No prescription information.
Evidence base: Russian-language clinical literature, primarily from the St. Petersburg Institute of Bioregulation and Gerontology (Khavinson school), 1985 onward. Not extensively peer-reviewed in Western journals.
No direct fat loss data in indexed literature; classified as cartilage/bone bioregulator, not lipolytic agent.
| Outcome | Finding |
|---|---|
| Fat loss evidence | None — primary target is cartilage and bone tissue, not adipose |
- — Unknown due to lack of human clinical trial data
- — Active malignancy (theoretical; peptide bioregulators may influence cell proliferation pathways)
- 01Route
Subcutaneous injection typical for Khavinson bioregulators; specific protocols not detailed in indexed literature.
- 02Frequency
Russian-tradition protocols often employ 10-day cycles; precise frequency unspecified in available abstracts.
- 03Storage
Lyophilised peptide bioregulators typically stored at 2–8 °C, light-protected. Reconstitution details not indexed.
Sources
of 32 rendered claims carry a resolvable citation.
- [linkova-2023]Linkova 2023 — Peptide Regulation of Chondrogenic Stem Cell Differentiation.
journal, 2023 - [povorozniuk-2007]Povorozniuk 2007 — [Effect of peptide regulators on the structural and functional status of bone tissue in ageing rats].
journal, 2007